An Australian pharmaceutical firm that is developing the first virus-killing nasal spray for colds is set to be listed on the ASX on Jan. 28.
Firebrick Pharma co-founder Peter Molloy said he’s been working on the spray, Nasodine, for almost ten years as a treatment for the common cold.
